March 24th 2023
Learning more about the early AD stages, when brain damage is limited, should allow early and more efficacious treatment, and improvements in imaging may be able to pick up changes earlier.
Study: Fovea-involving half dose of PDT proves a safe, long-term treatment option for chronic CSCMarch 3rd 2023
According to researchers, patients with chronic CSC treated with 1 fovea-involving, half-dose PTD application had a significant improvement in structure and function at the final follow-up and foveal atrophy did not develop in any patients.
APAO 2023: Beveled tip probe an all-in-one instrument for retinal detachment vitrectomyFebruary 24th 2023
Yusuke Oshima, MD, PhD, in a presentation at the 38th Asia-Pacific Academy of Ophthalmology Congress, Kuala Lumpur, Malaysia, discussed the advantages of using a beveled-tip ultra-speed probe for complete vitreous shaving during retinal detachment vitrectomies.
APAO 2023: Tenaya and Lucerne studies 1 year results: A closer look at anatomic outcomes In matched comparisonFebruary 23rd 2023
Analysis of data from the pooled Tenaya and Lucerne studies showed the faricimab achieved greater anatomic improvements compared to aflibercept during the matched-dosing period.
Pegcetacoplan approved by FDA for geographic atrophy secondary to AMDFebruary 17th 2023
Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD. This news follows the submission of the 24-month phase 3 data in November 2022.
DR/DME: Ongoing Clinical Trials and New Diagnostic ToolsFebruary 17th 2023
Carolyn Majcher, OD, FAAO, and Rishi Singh, MD, discuss new and upcoming clinical trials, investigational therapies, and diagnostic tools for the treatment of diabetic retinopathy and diabetic macular edema (DR/DME).
Reducing Treatment Burden of DR/DMEFebruary 17th 2023
Diabetic retinal disease experts discuss different approaches that can reduce the treatment burden while maintaining good visual outcomes during diabetic retinopathy and diabetic macular edema (DR/DME) therapy.
FDA accepts NDA, grants priority review to Iveric Bio for avacincaptad pegol for the treatment of geographic atrophyFebruary 17th 2023
The company announced a PDUFA goal date of Aug. 19, 2023. The FDA has not identified any potential review issues and is not currently planning to hold an Advisory Committee meeting for avacincaptad pegol.
Survey: What US and European retina specialists do and don’t know about biosimilarsFebruary 15th 2023
The survey addressed topics that would facilitate a better understanding of the awareness of retina specialists regarding this relative new form of treatment in ophthalmology.
EnVision Summit 2023: Unique program takes family friendly conference to new heightsFebruary 13th 2023
Bonnie An Henderson, MD, founder and program director of EnVision Summit, previews what attendees can expect at this year’s meeting - from its diverse faculty to an inclusive Youth Program, while also giving back to the community. The conference will take place February 17 to 20 at the El Conquistador Resort in Fajardo, Puerto Rico.
New phase III data show faricimab rapidly improved vision, reduced retinal fluid in patients diagnosed with retinal vein occlusionFebruary 10th 2023
Roche announced that faricimab met its primary endpoint in two clinical trials, BALATON and COMINO, showing non-inferior visual acuity gains compared to aflibercept.
Endogena Therapeutics receives FDA fast track designation for retinitis pigmentosa treatmentFebruary 7th 2023
According to the company, EA-2353 takes a novel, small-molecule approach and selectively activates endogenous retinal stem and progenitor cells, which differentiate into photoreceptors and can potentially preserve or restore visual function.
CLOSE study offers updated surgical classification for treating large full-thickness macular holesFebruary 6th 2023
According to investigators, a new proposed classification for large and extra-large full-thickness macular holes is based on the surgical results achieved with different surgical techniques
Foundation Fighting Blindness to kick off PRPH2 and Associated Retinal Diseases WorkshopJanuary 30th 2023
The workshop is designed to bring together leading experts from academia and industry, to discuss openly, and in detail, what is known about PRPH2 disease pathology, disease models, clinical characteristics, and therapeutic approaches.
Researchers unravel why episodes of low blood sugar worsen eye disease in people with diabetesJanuary 29th 2023
Patients diagnosed with diabetic retinopathy may be particularly vulnerable to periods of low glucose, and keeping glucose levels stable should be an important part of glucose control.
Poll: How familiar are you on the approval process for biosimilar drugs in comparison to new drug applications to the FDA?January 27th 2023
Let us know how familiar are you on the approval process for biosimilar drugs compared with new drug applications to the FDA. The poll will be open until February 28, 2023.